Author

Peter W. Nagle

Western General HospitalORCID 0000-0001-6150-2571Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Alison F. MunroiD· 2 shared Camilla DrakeiD· 2 shared Daniel V. EbneriD· 2 shared Gillian M. Morrison· 2 shared John C. DawsoniD· 2 shared Margaret C. FrameiD· 2 shared Muhammad FurqaniD· 2 shared Neil O. CarragheriD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alison F. MunroORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyiSciencePeer-reviewedApr 27, 2026

A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models

Richard J. R. Elliott, Peter W. Nagle, Muhammad Furqan…·Neil O. Carragher

This study screens a large compound library across patient-derived GBM stem cells to identify effective drugs targeting tumor heterogeneity and presents validated hits for further exploration.

3 citationstop 3%

humanproteomics

𝕏 PostBluesky

Cancer BiologyPharmaceuticsPeer-reviewedApr 23, 2025

Drug combinations targeting FAK and MEK overcomes tumour heterogeneity in glioblastoma

Muhammad Furqan, Richard J. R. Elliott, Peter W. Nagle…·Neil O. Carragher

This study identifies a synergistic combination of FAK and MEK inhibitors that effectively targets glioblastoma heterogeneity and improves therapeutic outcomes.

11 citationstop 3%

humanbulk RNA-seq

𝕏 PostBluesky